Switch to Budesonide Tablets Improve Remission in EoE
TOPLINEPatients with eosinophilic esophagitis (EoE) who switched from budesonide viscous solution (BVS) to budesonide orodispersible tablets (BOT) at the same dose and schedule experienced significant improvements in histological and deep histological remission rates. Endoscopic scores also improved significantly, and health-related quality of life (HRQOL) increased, though a numeric rise in endoscopic suspicion of candidiasis was observed. IN PRACTICE"BOT may be a potential rescue option in patients who fail BVS therapy, prior to escalation of (biological) treatment strategies," wrote the authors of the study.SOURCEThe study was led by Jana Defrancq, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
- ▪TOPLINEPatients with eosinophilic esophagitis (EoE) who switched from budesonide viscous solution (BVS) to budesonide orodispersible tablets (BOT) at the same dose and schedule experienced significant improvements in histological and deep h
- ▪Endoscopic scores also improved significantly, and health-related quality of life (HRQOL) increased, though a numeric rise in endoscopic suspicion of candidiasis was observed.
- ▪IN PRACTICE"BOT may be a potential rescue option in patients who fail BVS therapy, prior to escalation of (biological) treatment strategies," wrote the authors of the study.SOURCEThe study was led by Jana Defrancq, Department of Chronic Dis
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape Medical News Headlines |
| Canonical URL | https://www.medscape.com/viewarticle/switch-budesonide-orodispersible-tablets-viscous-solution-2026a1000p84?src=rss |
| Publication time | Fri, 24 Jul 2026 10:23:58 EDT |
| Retrieval time | 2026-07-25T04:44:09.405Z |
| Last seen | 2026-07-25T04:44:09.405Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | FPvllWvmwLmH |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINEPatients with eosinophilic esophagitis (EoE) who switched from budesonide viscous solution (BVS) to budesonide orodispersible tablets (BOT) at the same dose and schedule experienced significant improvements in histological and deep histological remission rates. Endoscopic scores also improved significantly, and health-related quality of life (HRQOL) increased, though a numeric rise in endoscopic suspicion of candidiasis was observed. METHODOLOGYResearchers conducted a retrospective analysis of a prospectively collected dataset including 45 adult patients with EoE who switched from BVS to BOT at the same dose (1 mg) and dosing schedule (32 patients switched in a once-daily [OD] schedule; 13 in a twice-daily schedule) at University Hospitals Leuven, Belgium.Patients had been on BVS…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape Medical News Headlines.
Discussion
0 commentsMore from Medscape Medical News Headlines
